A Study to Evaluate the Effect of Itraconazole on Pharmacokinetics (PK) of SHR8554 in Healthy Adult Subjects

Inclusion criteria

• Healthy male and female subjects, aged 18 to 45 years (inclusive).
• Female subjects body weight≥45 kg, male subjects body weight≥50 kg, body mass index (BMI) of 19.0 to 26.0 kg/m2 (inclusive).
• Understand the study procedures in the informed consent form and be willing and able to comply with the protocol.

Exclusion criteria

• Subjects with a history of drug allergy, or a history of specific allergies, or known allergy to SHR8554 or itraconazole or similar.
• Any condition or disease detected during the medical interview/physical examination that would render the participant unsuitable for the study as determined by the investigator.
• Subjects with positive tests for infectious diseases.
• Subjects who have undergone major surgery within 3 months prior to screening or have undergone surgery that could significantly affect the in vivo course or safety evaluation of the study drug.
• History of using any medication within 2 weeks prior to the first dosing.
• Subjects who have received vaccination within 1 month prior to screening or plan to receive vaccination during the trial.
• Excessive daily consumption of tea, coffee, grapefruit/grapefruit juice and other special diets in the 1 month prior to screening.
• Subjects with a history of substance abuse, drug use or a positive screening test for substance abuse.
• Female who are pregnant or breastfeeding, or have a positive pregnancy test.
• Subjects who may not be able to complete the study for other reasons or who the investigator believes should not be included.